Key Points
- Insider sale: Sarah Duncan sold 164,612 shares of NIOX (LON:NIOX) on April 16 at an average price of GBX 56, for a total of £92,182.72.
- Shares opened at GBX 57.40 (trading up 1.4%), with a 12‑month range of GBX 53.84–77.60, a market cap of £239.97 million, P/E of 35, and 50‑/200‑day moving averages of GBX 60.68 and 66.40.
- Analyst view: Deutsche Bank cut its target from GBX 90 to GBX 86 but kept a "buy" rating, leaving the consensus rating and average target at Buy / GBX 86.
NIOX Group Plc (LON:NIOX - Get Free Report) insider Sarah Duncan sold 164,612 shares of NIOX Group stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of GBX 56, for a total value of £92,182.72.
NIOX Group Trading Up 1.4%
Shares of NIOX stock opened at GBX 57.40 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.81 and a debt-to-equity ratio of 1.36. The business has a 50-day moving average price of GBX 60.68 and a two-hundred day moving average price of GBX 66.40. NIOX Group Plc has a 12-month low of GBX 53.84 and a 12-month high of GBX 77.60. The firm has a market cap of £239.97 million, a P/E ratio of 35.00 and a beta of 0.92.
NIOX Group (LON:NIOX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 24th. The company reported GBX 4.03 earnings per share (EPS) for the quarter. NIOX Group had a return on equity of 10.14% and a net margin of 14.37%. Equities analysts anticipate that NIOX Group Plc will post 1.1658256 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Deutsche Bank Aktiengesellschaft dropped their price target on NIOX Group from GBX 90 to GBX 86 and set a "buy" rating for the company in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of GBX 86.
View Our Latest Research Report on NIOX
About NIOX Group
(
Get Free Report)
NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.
Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
